A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor: BioAtla, Inc.
A PHASE2 clinical study on Head and Neck Cancer and Metastatic Cancer, this trial is completed. The trial is conducted by BioAtla, Inc. and has accumulated 10 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2023 — Oct 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BioAtla, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .